opregen emerging drug insight and market forecast

“OpRegen- Market Size, Forecast, and Emerging Insight – 2030” the report provides comprehensive insights about an investigational product for Geographic Atrophy in 7 Major Markets. A detailed picture of the OPREGEN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product.The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary

OpRegen is an investigational therapy in which retinal pigment epithelial (RPE) cells are introduced into the subretinal space where they are intended to replace missing RPE cells. The ongoing trial is a Phase I/IIa dose escalation study evaluating the safety and efficacy of three different dose regimens of OpRegen in patients with the advanced form of dry-AMD accompanied by geographic atrophy. Data recently presented from the first patient cohort indicate that at the first dose, OpRegen caused no serious adverse events, and retinal imaging suggests the presence and survival of transplanted cells in the subretinal space for up to one year.

Scope of the report

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around OPREGEN.
• The report contains forecasted sales for OPREGEN till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Geographic Atrophy.
• The report also features the SWOT analysis with analyst insights and key findings of OPREGEN.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OPREGEN Analytical Perspective by DelveInsight

• In-depth OPREGEN Market Assessment

This report provides a detailed market assessment of OPREGEN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

• OPREGEN Clinical Assessment

The report provides the clinical trials information of OPREGEN covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights  

• In the coming years, the market scenario for Geographic Atrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies and academics are working to assess challenges and seek opportunities that could influence OPREGEN dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Geographic Atrophy are giving market competition to OPREGEN and launch of late-stage emerging therapies in the near future will significantly impact the market.  
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of OPREGEN.
• Our in-depth analysis of the forecasted sales data of OPREGEN from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OPREGEN. 

Key Questions

• Which company is developing OPREGEN along with the phase of the clinical study?
• What is the technology utilized in the development of OPREGEN?
• What is the product type, route of administration and mechanism of action of OPREGEN?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OPREGEN development?
• What are the key designations that have been granted to OPREGEN?
• What is the forecasted market scenario of OPREGEN?
• What is the history of OPREGEN and what is its future?
• What is the forecasted sales of OPREGEN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  
• What are the other emerging products available and how these are giving competition to OPREGEN?
• Which are the late-stage emerging therapies under development for the treatment of the Geographic Atrophy?